3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
36
Triple Negative Breast Neoplasms
32
Carcinoma, Non-Small-Cell Lung
11
Carcinoma, Transitional Cell
10
Urinary Bladder Neoplasms
9
Neoplasm Metastasis
7
Lung Neoplasms
5
Endometrial Neoplasms
4
Small Cell Lung Carcinoma
3
Ovarian Neoplasms
3
Glioblastoma
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Urothelial Bladder Carcinoma
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Interventions
pembrolizumab
188
Cisplatin
47
Paclitaxel
45
Carboplatin
44
lenvatinib
31
Docetaxel
23
Pemetrexed
21
Fluorouracil
20
Capecitabine
17
Gemcitabine
15
Oxaliplatin
14
Saline Solution
13
Albumin-Bound Paclitaxel
11
130-nm albumin-bound paclitaxel
10
epacadostat
9
Leucovorin
9
Cetuximab
9
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
enzalutamide
5
belzutifan
5
Dexamethasone
5
durvalumab
4
Surgical Procedures, Operative
4
Radiotherapy
4
Nivolumab
4
trifluridine tipiracil drug combination
3
spartalizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
sacituzumab govitecan
×
Clear all
NCT05609968
2025-12-24
MK-3475-D46
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
614 enrolled